
    
      The efficacy and safety of Surfactant-BL will be evaluated in terms of mean duration of
      oxygen therapy (days) after hospitalization, in adult patients with ARDS due to SARS-COV-19
      infection.

      Adult patients with COVID-19 induced respiratory failure will be receive either standard
      treatment or standard treatment plus Surfactant-BL.
    
  